KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.

KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。

youdao

ACE inhibitor, ARB, et al. single therapy, 59 CKD incidences 50.9% in 116 patients with calcium channel blocker CCB and RAS inhibitor combination therapy.

ACE抑制剂、ARB等单药治疗的患者中；59例50.9%发生在116例接受钙通道阻滞剂CCB和RAS抑制剂联合治疗的患者中。

youdao